Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Evlarco
product2 mentionslast seen Sep 21, 2026
Fixed-dose combination of 10 mg obicetrapib plus 10 mg ezetimibe approved for primary hypercholesterolaemia.
Relationships 7
- Menarini GroupcommercializesEvlarco99% confidence2 sources
- European CommissionapprovesEvlarco99% confidence2 sources
- Evlarcocomposed ofezetimibe95% confidence1 source
- Evlarcocomposed ofobicetrapib95% confidence1 source
- Evlarcoapplies toprimary hypercholesterolaemia treatment90% confidence1 source
- NewAmsterdam Pharma Company N.V.developsEvlarco90% confidence1 source
- Evlarcoapplies tocardiovascular disease treatment88% confidence1 source
Relationship
Menarini GroupcommercializesEvlarco
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARSep 21, 2026NewAmsterdam Pharma Co N.V. 8-K: Item 8.01: Other Events
Menarini holds exclusive commercialization rights for obicetrapib in Europe
- newsPR NewswireSep 21, 2026Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Menarini holds exclusive commercialization rights for obicetrapib in Europe